Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
53 results about "Maitansine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Maitansine (INN), or maytansine (USAN), is a cytotoxic agent. It inhibits the assembly of microtubules by binding to tubulin at the rhizoxin binding site. It is a macrolide of the ansamycin type and can be isolated from plants of the genus Maytenus.
Cytotoxic agents comprising new maytansinoids
ActiveUS7276497B2Improve anti-tumor activityImprove biological activityOrganic active ingredientsOrganic chemistryAnimal tumorEfficacy
New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the α-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.
Owner:IMMUNOGEN INC
Drug conjugate composition
ActiveUS7374762B2Snake antigen ingredientsAntibody ingredientsDrug conjugationAntiendomysial antibodies
Owner:IMMUNOGEN INC
Preparation of maytansinoid antibody conjugates by a one-step process
ActiveUS20120253021A1High purityImprove stabilityOrganic active ingredientsPeptide preparation methodsChemistryBy-product
The invention provides a one-step process for preparing a cell-binding agent cytotoxic agent conjugate comprising contacting a cell-binding agent with a cytotoxic agent to form a first mixture comprising the cell-binding agent and the cytotoxic agent and contacting the first mixture comprising the cell-binding agent and the cytotoxic agent with a bifunctional crosslinking reagent, which provides a linker, in a solution having a pH of about 4 to about 9 to provide a second mixture comprising the cell-binding agent cytotoxic agent conjugate, wherein the cell-binding agent is chemically coupled through the linker to the cytotoxic agent, free cytotoxic agent, and reaction by-products. The second mixture is then optionally subjected to purification to provide a purified cell-binding agent cytotoxic agent conjugate.
Owner:IMMUNOGEN INC
Anti-integrin immunoconjugates, methods and uses
The invention relates to conjugates of anti-integrin specific antibodies with cytotoxic compounds, the synthesis, selection, and use of such conjugates for use in cancer therapy or other diseases mediated by cell proliferation, cell migration, or inflammation and which pathology involves angiogenesis or neovascularization of new tissue. In addition the invention relates to combination therapy of such diseases wherein the treatment comprises use of said conjugates in combination with one or more other treatment modalities including but not limited to: chemotherapy, surgery or radiation therapy. The preferred conjugates contain maytansinoid compounds linked to the antibody by a disulfide linkage, and preferred chemotherapeutic agents are doxorubicin, a taxane, a camptothecin, a podophyllotoxin, a nucleoside analog, or a pyrimidine analog.
Owner:IMMUNOGEN INC +1
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
Methods and compositions for the development of effective cancer therapies using mitotic inhibitors which have limited general toxicity to normal, non-cancerous cells and tissues are provided. The methods and compositions utilize cytotoxic compounds comprised of a cell-binding agent (e.g., antibodies) conjugated to an anti-mitotic compound (e.g., maytansinoids). The invention further provides antibodies which are substantially incapable of inducing antibody-dependent cell-mediated cytotoxicity (ADCC) and / or complement dependent cytotoxicity (CDC), thereby ensuring that the therapeutic effect is mediated primarily by the anti-mitotic component of the cytotoxic compound, rather than by indirect cell killing via ADCC and / or CDC. The antibodies of the invention further are capable of differentiating between polypeptide antigens which are more highly expressed on proliferating cancer cells as compared to proliferating non-cancer cells.
Owner:GENENTECH INC
Methods for preparation of antibody-maytansinoid conjugates
ActiveUS8624003B2Organic active ingredientsHybrid immunoglobulinsAntiendomysial antibodiesMaitansine
Owner:IMMUNOGEN INC
Drug conjugate composition
InactiveUS7494649B2Snake antigen ingredientsAntibody ingredientsAntiendomysial antibodiesPharmaceutical drug
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.
Owner:IMMUNOGEN INC
Process for preparing stable antibody maytansinoid conjugates
InactiveUS20150306242A1Organic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsCell bindingCytotoxicity
The invention provides processes for manufacturing cell-binding agent-cytotoxic agent conjugates of improved stability comprising performing the modification reaction at a high pH. The inventive processes comprise contacting a cell-binding agent with a bifunctional crosslinking reagent in a solution having a pH of 7.1 to 9 to covalently attach a linker to the cell-binding agent and thereby prepare a mixture comprising cell-binding agents having linkers bound thereto.
Owner:IMMUNOGEN INC
Drug conjugate composition
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.
Owner:IMMUNOGEN INC
Preparation of maytansinoid antibody conjugates by a one-step process
ActiveUS20140309406A1High purityImprove stabilityPeptide preparation methodsImmunoglobulinsAntiendomysial antibodiesAntibody conjugate
Owner:IMMUNOGEN INC
Mutant Actinosynnema pretiosum strain with increased maytansinoid production
InactiveUS7192750B2Reduce the amount of solutionIncrease productionOrganic chemistryBacteriaBiotechnologyMicroorganism
Owner:IMMUNOGEN INC
Novel chemotherapeutic drug nano ADC based on antibody conjugation and preparation method and application thereof
ActiveCN104491868AHigh affinityGood targetingPowder deliveryOrganic active ingredientsTumor targetDoxorubicin
The invention discloses nanoparticles of an antibody chemotherapeutic drug such as doxorubicin and maytansine (DOX, DM1) based on an antibody conjugation new technology and a preparation method and an application thereof. Experimental results show that compared with a single antibody and a single drug, nanoparticles formed by self-assembling antibody-chemotherapeutic drug conjugated conjugates has a targeting property significantly enhanced, and has the drug toxic and side effects on bodies significantly reduced; the formed nanoparticles use enhanced permeability and retention effect (EPR) of tumor tissues in a composite mode to enhance intratumoral accumulation, enhances the bioavailability of the drug, at the same time, reduces the use dosage of the drug, and provides a high-efficiency and low-toxicity nano treatment mode for tumor targeted therapy.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Maytansinoid derivatives
ActiveUS8877706B2Prevent relapseUndesirable side-effectOrganic active ingredientsPeptide/protein ingredientsDiseaseMedicine
Owner:BIO THERA SOLUTIONS LTD
Combination therapy for the treatment of cd19+ b-cell malignancies symptoms comprising an Anti-cd1 maytansinoid immunoconjugate and rituzimab
A combination of an anti-CD19 maytansinoid immunoconjugate and rituximab is used for treating CD19+CD20+ B-cell malignancies symptom, in particular Non-Hodgkin's lymphoma.
Owner:SANOFI SA
Improved cytotoxic agents comprising new maytansinoids
New thiol and disulfide-containing maytansinoids bearing a mono or di-alkyl substitution on the alpha-carbon atom bearing the sulfur atom are disclosed. Also disclosed are methods for the synthesis of these new maytansinoids and methods for the linkage of these new maytansinoids to cell-binding agents. The maytansinoid-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.
Owner:IMMUNOGEN INC
Mutant actinosynnema pretiosum strain with increased maytansinoid production
InactiveUS20050003513A1Reduce the amount of solutionEnhanced maytansinoid productionOrganic chemistryBacteriaBiotechnologyMicroorganism
A microorganism that is a mutant bacterial strain of the species Actinosynnema pretiosum, designated PF4-4, (ATCC PTA-3921), being capable of producing maytansinoid ansamitocins such as ansamitocin P-3 in improved yield compared to previous known strains, and capable of growth under varied culture conditions, and methods of producing maytansinoid ansamitocins by culturing PF4-4 in a suitable growth medium.
Owner:IMMUNOGEN INC
Methods of treatment using Anti-erbb antibody-maytansinoid conjugates
InactiveUS20200048362A1Superior clinical activityBetter objective response ratePharmaceutical delivery mechanismImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesOncology
The application concerns methods of treatment using anti-ErbB receptor antibody-maytansinoid conjugates, and articles of manufacture suitable for use in such methods. In particular, the invention concerns ErbB receptor-directed cancer therapies, using anti-ErbB receptor antibody-maytansinoid conjugates.
Owner:IMMUNOGEN INC +1
Cytotoxic agents comprising new maytansinoids
Owner:IMMUNOGEN INC
Drug conjugate composition
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.
Owner:IMMUNOGEN INC
Drug conjugate composition
The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that the antibody binds to the surface of the cell and the cytotoxicity of the maytansinoid is activated, whereby the cell is killed.
Owner:IMMUNOGEN INC
Peptide conjugates of microtubule-targeting agents as therapeutics
The present invention relates to peptide conjugates of microtubule-targeting agents such as maytansinoid derivatives which are useful for the treatment of diseases such as cancer.
Owner:CYBREXA 3 INC
Anti-integrin immunoconjugates, methods and uses
InactiveUS8603483B2Effective rate of releaseSenses disorderAntipyreticDiseaseAntiendomysial antibodies
Owner:IMMUNOGEN INC +1
Process of preparing antibody-drug conjugate
InactiveUS20180311375A1Affect safety and efficacyImprove purityOrganic active ingredientsPeptide preparation methodsMaytansinoidOrganic chemistry
The invention provides process for preparing antibody-drug conjugates, preferably trastuzumab maytansinoid conjugate linked via non-cleavable linker comprising performing the conjugation reaction at lower temperature than ambient and / or at lower pH condition than neutrality. The process according to the present invention comprises conjugating the linker modified antibody with cytotoxic drug, preferably the SMCC-modified trastuzumab with a cytotoxic drug, preferably maytansinoid at a temperature lower than 20° C. and at a pH lower than 6.0, and thereby preparing an antibody-drug conjugate, preferably trastuzumab maytansinoid conjugate, T-DM1.
Owner:CADILA HEALTHCARE LTD
Polypeptide prodrug modified by Evans blue as well as preparation and application thereof
ActiveCN108690119AEasy to makeSmall toxicityOrganic active ingredientsTetrapeptide ingredientsCancer cellMedicine
The invention provides polypeptide prodrug, which is prodrug formed by monomethyl dolastatin medicine or Maitansine and Evans blue. A structure formula of the polypeptide prodrug is shown as a formula(I), wherein R1 is one kind of materials from a material shown in the description or -CH2-; R2 is one kind of materials from polypeptide medicine of monomethyl dolastatin or Maitansine structures; mand n are repeated unit number and are integers being 0 to 4. The polypeptide medicine prodrug has the excellent tumor cell taking effects in vivo and in vitro; a part of prodrug also shows the obvious cancer cell inhibition effects. The invention also provides a preparation method of the prodrug and application of the prodrug in the cancer treatment medicine. (The formula is shown in the description.).
Owner:SHANGHAI THERANOSTICS BIOTECH CO LTD
Anti-mesothelin immunoconjugates and uses therefor
ActiveUS20170327589A1Good curative effectImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesAntibody fragments
The present invention provides immunoconjugates composed of antibodies, e.g., monoclonal antibodies, or antibody fragments that bind to mesothelin, that are conjugated to cytotoxic agents, e.g., maytansine, or derivatives thereof, and / or co-administered or formulated with one or more additional anti-cancer agents. The immunoconjugates of the invention can be used in the methods of the invention to treat and / or diagnose and / or monitor cancers, solid tumors, recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for the membrane-anchored, 40 kDa mesothelin polypeptide, which which is overexpressed in several tumors, such as pancreatic and ovarian tumors, mesothelioma and lung cancer cells.
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Methods of treating HER2-positive metastatic breast cancer
Owner:GENENTECH INC
Maytansinoid derivatives
ActiveUS20140178414A1Minimizing undesirable side effectPrevent relapseOrganic active ingredientsAntipyreticDiseaseMedicine
Disclosed herein are maytansinoid drug linker derivatives which can be linked to a antigen binding unit (Abu), and maytansinoid drugs linked with an antigen binding unit (Drug-Linker-Antigen binding Unit: D-L-Abu), for targeted delivery to disease tissues. D-L-Abu, D-L-Abu derivatives, and methods relating to the use of such drug conjugates to treat antigen positive cells in cancers and immunological disorders are provided.
Owner:BIO THERA SOLUTIONS
Anti-cd22 antibody-maytansine conjugates and methods of use thereof
PendingUS20200246480A1Efficient releaseMultiple functionsOrganic active ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsAntiendomysial antibodiesBiochemistry
The present disclosure provides anti-CD22 antibody-maytansine conjugate structures. The disclosure also encompasses methods of production of such conjugates, as well as methods of using the same.
Owner:R P SCHERER TECH INC
Anti-mesothelin immunoconjugates and uses therefor
ActiveUS10647779B2Good curative effectImmunoglobulins against cell receptors/antigens/surface-determinantsAntibody ingredientsAntiendomysial antibodiesAntibody fragments
Owner:BAYER INTELLECTUAL PROPERTY GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com